Cagent Vascular Raises $41M Series D for IVL Technology

Cagent Vascular has successfully closed a substantial $41 million Series D funding round, an oversubscribed financing event that underscores investor confidence in its innovative intravascular lithotripsy (IVL) technology. This capital infusion follows the system's initial human use, marking a significant milestone for the company as it aims to capture a larger share of the estimated $17 billion peripheral and coronary arterial markets.

The newly acquired funds are earmarked for the strategic advancement and commercial rollout of Cagent Vascular's unique dual-modality IVL platform. Specifically, the financing will propel the peripheral commercial launch of the Serranator SONIC IVL System and support the ongoing development of its coronary artery applications. This dual approach addresses a critical need in treating complex calcified lesions, a persistent challenge in vascular interventions.

At the heart of Cagent Vascular's innovation is the Serranator SONIC IVL System, which uniquely integrates the company's established Serranator Serration Remodeling Therapy (SRT) with a novel lithotripsy generator. This combination delivers ultrasonic acoustic waves through the device's serrated metal elements directly into calcified plaque. The technology is engineered to enhance vessel compliance at lower inflation pressures, offering a more effective solution for challenging lesion morphologies, including those with severe calcification and resistant fibrous plaque.

The system's design emphasizes physician-centric benefits, featuring a fully disposable unit that eliminates the need for capital equipment and provides physicians with granular control over energy delivery during procedures. This contrasts with existing IVL technologies, positioning Cagent Vascular's offering as a potentially more versatile and cost-effective solution for a broad range of patients. The initial human procedures, conducted as part of the prospective multicenter REMODEL I Study in Uzbekistan by Drs. S. Iskhakov, N. Madrakhimov, and Steven Kum, demonstrated promising results in calcium modification and lesion remodeling, as evidenced by angiographic and IVUS imaging.

The Series D financing was co-led by prominent venture capital firms U.S. Venture Partners (USVP) and Astoria Health Investors. These lead investors, alongside other participants, are backing Cagent Vascular's vision to expand its clinical footprint globally. The proceeds will also fund the pivotal REMODEL II trial, further validating the system's efficacy and safety in larger patient populations. The company's existing Serranator portfolio already boasts a national presence across major U.S. markets and select international territories, indicating a strong commercial foundation.

Industry experts highlight the synergistic potential of Cagent Vascular's combined approach. Dr. Peter Schneider, Chief Medical Advisor and Co-Founder, noted that the SONIC IVL System is "genuinely more than the sum of its parts," creating a synergistic effect not seen with standalone technologies. This integrated therapy aims to overcome the limitations of previous treatments that often required physicians to choose between separate SRT and IVL modalities. The successful first-in-human use and substantial funding position Cagent Vascular for significant growth in the high-demand interventional cardiology and peripheral vascular markets.